Aquestive Therapeutics (NASDAQ:AQST) Insider Peter Boyd Sells 29,814 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Peter Boyd sold 29,814 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $124,324.38. Following the completion of the sale, the insider directly owned 338,509 shares in the company, valued at $1,411,582.53. This represents a 8.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Aquestive Therapeutics Stock Performance

Shares of AQST traded up $0.11 during midday trading on Wednesday, hitting $4.31. The company had a trading volume of 1,170,828 shares, compared to its average volume of 5,614,740. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $7.55. The firm has a market capitalization of $525.38 million, a P/E ratio of -5.52 and a beta of 1.61. The company’s 50-day simple moving average is $4.13 and its 200-day simple moving average is $5.22.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million for the quarter, compared to analysts’ expectations of $13.28 million. Equities analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AQST. Vanguard Group Inc. lifted its position in shares of Aquestive Therapeutics by 30.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after buying an additional 1,333,627 shares during the last quarter. State Street Corp grew its position in shares of Aquestive Therapeutics by 53.7% in the 4th quarter. State Street Corp now owns 2,462,778 shares of the company’s stock valued at $15,910,000 after buying an additional 860,562 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Aquestive Therapeutics by 13.4% in the 4th quarter. Geode Capital Management LLC now owns 2,368,092 shares of the company’s stock valued at $15,301,000 after buying an additional 280,144 shares during the last quarter. Federated Hermes Inc. raised its stake in Aquestive Therapeutics by 159.4% during the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock worth $13,132,000 after acquiring an additional 1,249,044 shares in the last quarter. Finally, Pale Fire Capital SE raised its stake in Aquestive Therapeutics by 25.5% during the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after acquiring an additional 340,767 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on AQST shares. Lake Street Capital set a $6.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $8.80.

Trending Headlines about Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.